Signaling through the lymphotoxin beta receptor induces the death of some adenocarcinoma tumor lines by unknown
Signaling through the Lymphotoxin  13 Receptor  Induces 
the Death  of Some Adenocarcinoma  Tumor Lines 
By Jeffrey L. Browning, Konrad Miatkowski, Irene Sizing, 
David Griffiths, Mohammad Zafari, Christopher D. Benjamin, 
Werner Meier, and Fabienne Mackay 
From the Departments  of Immunology and Inflammation  and Protein Engineering, Biogen, 
Cambridge, Massachusetts  02142 
Summary 
Surface lymphotoxin (LT) is a heteromeric complex of LT-c~ and LT-[3 chains that binds to the 
LT-I3 receptor (LT-I3-R), a member of the tumor necrosis factor (TNF)  family of receptors. 
The biological function of this receptor-ligand system is poorly characterized. Since signaling 
through other members of this receptor family can induce cell death, e.g., the TNF and Fas re- 
ceptors, it is important to determine if similar signaling events can be communicated via the 
LT-13-tL. A soluble form of the surface complex was produced by coexpression of LT-c~ and a 
converted form of LT-[3 wherein the normally type II LT-[3 membrane protein was changed 
to a type I secreted form. Recombinant LT-oq/[32 was cytotoxic to the human adenocarcinoma 
cell lines HT-29, WiDr,  MDA-MB-468,  and HT-3 when added with the synergizing agent 
interferon (IFN) y. When immobilized on a plastic surface, anti-LT-[3-tL monoclonal antibod- 
ies  (mAbs) induced  the death  of these cells,  demonstrating direct signaling via the LT-I3-R. 
Anti-LT-[3-R mAbs were also identified that inhibited ligand-induced cell death, whereas others 
were found to potentiate the activity of the ligand when added in solution. The human WiDr 
adenocarcinoma line forms solid tumors in immunocompromised mice, and treatment with an 
anti-LT-~-R, antibody combined with human IFN-~/arrested tumor growth. The delineation 
of a biological signaling event mediated by the LT-I3-R opens a window for further studies on 
its immunological role, and furthermore, activation of the LT-I3-R may have an application in 
tumor therapy. 
T 
he TNF family ofligands and receptors is a set of reg- 
ulatory elements in the immune system (t). TNF was 
discovered as a  cytolytic agent circulating in  the blood of 
endotoxin-stimulated animals (2-4). Originally cloned in the 
expectation that TNF would be a novel antitumor agent, it 
was later shown that its primary physiologic function lies in 
initiating  the  inflammatory cascade  underlying  the  host's 
immediate defensive response to infection or stress.  More 
complex immunological functions have been described (5, 
6).  Lymphotoxin (LT) 1 e~  (also  called TNF-I3) is a similar 
cytokine  secreted  by  activated  lymphocytes  (7)  and  was 
originally  characterized  as  having  the  same  functions  as 
TNF. Later, activated T  and B  cells were found to display 
LT-c~ on their surfaces in an unusual form compIexed with 
another member of the TNF family called LT-13 in an LT- 
oq/132 stoichiometry (8-13).  A  complex with an apparent 
1  Abbreviations used in this paper: LT, lymphotoxin; LT-I3-1L,  LT-[3 recep- 
tor;  MTT,  3-(4,5-dimethylthiazol-2-yl) 2,5  diphenyltetrazolium bro- 
mide; TUNEL, terminal deoxynucleotidyl transferase UTP nick-end la- 
beling; VCAM, vascular  cell adhesion molecule. 
LT-c~2/I31 stoichiometry is also present, but only in minor 
amounts on human lymphocytes. The major LT-cq/f3 z form 
does not bind to the known TNF receptors, referred to here 
as TNF-R55 and TNF-R.75, but rather interacts with an- 
other receptor in the TNF family called the LT-[3 receptor 
(LT-[3-R) (9,  14). 
Currently, the function of the LT system is poorly char- 
acterized, however, there are suggestions that LT signaling 
is involved in the development of the peripheral lymphoid 
organs. Genetic disruption of the LT-0~ gene in mice led to 
an unusual phenotype. The mice lacked lymph nodes and 
lost the organization of T  and B  cells in the follicles in the 
spleen (15,  16). A similar loss of lymph nodes occurs in aly, 
mice  although  this  mouse,  unlike  the  LT-cc  knockout 
mouse,  is  severely  immunocompromised  (17).  Signaling 
through  the  two  known  TNF  receptors  has  not  been 
shown  to  mediate  the  development  of the  lymph  nodes 
since knockout of either receptor does not lead to the loss 
of lymph nodes (18,  19).  Thus, it has been postulated that 
signaling  through  the  LT-[3-tL  constitutes  a  regulatory 
pathway that is distinct from TNF-related events and may 
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mouse (12, 15, 16). 
Activation of several members of the TNF family of re- 
ceptors can have cytotoxic or growth-inhibitory consequences 
(1). For example Fas receptor activation results in apoptosis 
of many  cell types, including both  transformed and  non- 
transformed cells (20, 2I), and this process is likely to play a 
role in the deletion of autoreactive lymphocytes in the pe- 
riphery (22). TNF and LT-e~ also can kill some transformed 
cells, and it is hkely that tumor cells respond abnormally by 
either necrosing or apoptosing to what is normally a differ- 
entiation-hke signal. More recently, TNF signaling has been 
proposed to induce the death of nontransformed lympho- 
blasts in a slow fashion (23, 24), and this process appears to 
require  TNF-R75.  The  physiological significance of this 
event  remains  to  be  explored.  The  Fas  receptor and  the 
TNF-R,55 both possess a unique cytoplasmic domain, called 
the death domain, that is required to initiate cell death (25). 
CD30 and CD40 signaling can inhibit growth and may also 
induce  apoptosis, yet these receptors as well as the TNF- 
R75 and the LT-I3-R lack obvious death domains (12, 26, 
27). We have investigated whether LT-I3-R signaling could 
induce cell death both because of its possible immunologi- 
cal relevance  and  to provide a  practical starting point for 
studying the role of the LT system. Using either recombi- 
nant ligands or antireceptor mAbs with agonist activity, the 
ability of LT-[3-R activation to induce cell death in various 
transformed lines was  examined.  In this  report, we  show 
that  LT-I3-R signaling can  induce  cell death  in  a  limited 
group of adenocarcinoma tumor lines. 
Materials and Methods 
Cells.  All cells were obtained from American Type Culture 
Collection (ATCC) (Rockville, MD) except for WEHI 164 clone 
13, which was obtained from Dr. Eric Kawashima (Glaxo Insti- 
tute for Molecular Biology, Geneva, Switzerland). WEHI 164 cells 
were cultured in RPMI 1640 with 10% fetal bovine serum (FBS). 
HT-29  and WiDr cells were maintained in MEM with Earle's 
salts,  10% FCS with glutamine, penicillin/streptomycin, nones- 
sential amino acids, and sodium pyruvate. These two cell lines are 
thought to be derived from the same patient (28).  In our assays, 
the original ATCC HT-29 line was heterogenous in its response 
to LT-0tl/[32,  and not all of the cells died in a parallel manner. 
Subclones from the line were isolated by limiting dilution, and 
the  HT-29-14  line  was  one  subclone  that  behaved  homoge- 
nously in these assays. All of the results can be reproduced quali- 
tatively with the parental line. 
Materials.  The anti-Fas mAb CH11 was obtained from Kamiya 
Biomedical Co. (Thousand Oaks, CA), the control IgG1 mouse 
mAb MOPC 21 from Organon Technica (Durham, NC) and the 
anti-CD40 mAb BB20 from R&D Systems (Minneapolis, MN). 
The anti-human LFA-3 mAb 1E6  has been described (29)  and 
the anti-LFA-3 mAb TS2/9  was provided by Barbara Wallner. 
The anti-TNF mAb 104c has been described (30).  The HT-29/ 
26 hybridoma that produces a mAb that recognizes an abundant 
antigen on the HT-29  surface was obtained from ATCC,  cells 
were grown, and the mAb purified by protein A-Sepharose chro- 
matography. The LT-I3-R-hlgG1 and TNF-R55-hlgG1 Fc fu- 
sion proteins have been described (9). 
Recombinant Cytokines.  Human  TNF  and  IFN-~/ were pro- 
duced at Biogen (30). Recombinant human LT-et was prepared 
by expression in insect cells as described (31)  and was similar to 
material expressed in CHO cells (30). The recombinant LT-a/I~ 
heteromeric forms were prepared by coinfection of insect cells 
with two baculoviruses encoding the human  LT-et and human 
LT-13 proteins (Browning, J.L., K. Miatkowski, D.A.  Gritfiths, 
P.R. Bourdon, C. Hession, C.M. Ambrose, and W. Meier, manu- 
script in preparation). The transmembrane region of the LT-13 gene 
was  replaced with  a  vascular cell adhesion  molecule  (VCAM) 
leader sequence to enable secretion of mixed LT-~/[~ forms. The 
trimers  LT-0qf~2,  LT-otff131,  and  LT-0t  3 were  purified  using 
combinations of p55 TNF-R and LT-13-R aflfimty columns. The 
resultant preparations have been well characterized, contain only 
LT forms, are trimerie, and are >95% pure with respect to LT 
forms based on ion exchange chromatographic resolution of the 
three stoichiometrically different trimers. The LT-eq/[32 prepara- 
tion contained <1 part in 5,000 of LT-%-like activity as assessed 
using the WEHI 164 indicator line and by comparison of various 
LT trimers prepared with a LT--ot D50N mutation that eliminates 
TNF-R binding (Browning J.L.,  K.  Miatkowski, D.A.  Griffiths, 
P.R.. Bourdon, C. Hession,  C.M. Ambrose, and W. Meier, manu- 
script in preparation). 
Cytotoxicity Assays.  In the cytotoxicity assays, serial dilutions 
of the cytokines or antibodies were prepared in 50 wl in 96-well 
plates, and 5,000 HT-29-14 cells were added in 50 I~1 of media 
with or without IFN-~. After 3-4 d, 10 wl of 5 mg/ml MTT [3- 
(4,5-dimethylthiazol-2-yl) 2,5 diphenyltetrazolium bromide] was 
added, and after 3 h the formazan was dissolved by adding 100 I~1 
of 10% SDS in 10 mM HC1.  After a further 24-h incubation at 
37~  the OD was quantitated at 550 nm. In some experiments, 
soluble receptor forms or pure human lgG were added in 10 I.d 
before the addition of the cells. To immobilize mAbs on the plas- 
tic surface, 96-well tissue culture plates were first coated with 50 
I~1 of 10  Ixg/ml affinity-purified goat anti-mouse Fc polyclonal 
antibody  0ackson  ImmunoResearch  Laboratories,  Inc.,  West 
Grove, PA), washed with 5% FBS in PBS, and then coated with 
varying amounts of the various mAbs diluted into tissue culture 
media with FBS. The plates were washed with media before use. 
Cells were added and growth assessed as indicated above. To sur- 
vey the panel of cells shown in Table 4,  cells were plated in the 
presence of 50 U/ml IFN-'y with various dilutions of TNF, anti- 
Fas, LT-eq/132,  or into wells coated with various anti-LT-[3-R 
mAbs as described above. Growth was assessed with the MTT 
readout, and wells were also  visually inspected for morphology 
changes.  Dramatic growth inhibition was  scored as two  pluses 
(+ +), partial growth inhibition at reasonable concentrations was 
noted as one plus (+), and partial effects requiring high concen- 
trations ofhgand was marked as plus/minus (+/-). 
Mouse Anti-LT-fl-R mAbs.  Mouse hybridomas producing mAbs 
to the human LT-I3-R were prepared by immunization of RBF 
mice with the LT-13-R-Fc chimera essentially as described previ- 
ously (9). All mAbs were IgG1 isotypes. 
FACS  ~ Binding Assays.  To monitor receptor binding to sur- 
face hgand, 200 ng/ml soluble LT-13-R-Fc were added to PMA- 
activated II-23 T  cell hybridoma cells, and binding was detected 
using a PE-labeled donkey anti-human Ig essentially as described 
(9). To assess the blocking ability of the mAbs, mAbs were prein- 
cubated with the soluble receptor for 20 rain before addition of 
the receptor-mAb mixture to the  II-23  cells.  In other experi- 
ments,  receptor expression on  adherent tumor lines was deter- 
mined by FACS  |  analysis of cells removed with PBS with 5 mM 
EDTA and stained using anti-LT-[3-R mAbs and a PE-labeled 
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oratories). 
Epitope Mapping by BIAcore  TM Analysis.  Atfinity-purified goat anti-- 
human Fc (Jackson ImmunoResearch Laboratories)  was immobi- 
lized onto an N-hydroxysuccinimide--activated sensor  chip, and 
LT-13-R-Fc was captured onto the anti-human-Fc-coated chip. 
The various pairs  of anti-LT-[3-R mAbs were then bound se- 
quentially, and the ability of  the second mAb to bind in the presence 
of the first mAb was measured using a BIAcore  TM 2000 (Pharma- 
cia  Biosensor,  Uppsala,  Sweden).  The  entire  array  of 49  mAb 
combinations were assessed for cross-blocking in this manner and 
analyzed essentially as described  (32). 
Analysis of  Apoptosis.  Terminal deoxynucleotidyl transferase UTP 
nick-end  labeling  (TUNEL)  of ~ee  DNA  ends,  i.e.,  TUNEL 
staining,  was carried  out using the ApopTag  TM  kit (Oncor Inc., 
Gaithersburg,  MD) according to the manufacturer's specifications. 
Tumor Growth in SCID Mice.  BALB/c SCID female  mice at 
6-8 wk old (The Jackson Laboratory, Bar Harbor, ME) were in- 
jected with 106 trypsinized  and washed WiDr cells in a volume of 
0.2 ml of PBS subcutaneously onto the back of the animal.  Mice 
were treated with or without antibody either with or without 106 
antiviral  U/mouse of human IFN-~ by intraperitoneal injection 
in 0.2 ml on days 0 and 1 or as indicated. The amounts of IFN-~ 
and antibody have not been optimized. Tumor volume was cal- 
culated from the radius as determined by caliper measurements in 
two dimensions.  The results shown in Fig. 6 B were determined 
in a blinded format. 
Results 
LT-otl/fl2 Is Cytotoxic  to HT-29 Ce~.  Recombinant LT-oq/ 
132 and LT-~x2/13 t trimers were tested for their ability to in- 
hibit  the  growth of a  number of tumor lines.  IFN-~/ was 
included in the screening as it had been shown to enhance 
the cytolytic properties of TNF (33). Recombinant soluble 
LT-oq/132 inhibited the growth of human HT-29 cells only 
in the presence ofIFN-~/(Fig.  1) and, as shown previously, 
this cell line was also sensitive to the anti-Fas receptor mAb 
CH11,  TNF,  and LT-oe (30,  34, 35).  IFN-ot and -13 were 
100-fold less effective when compared on the basis of anti- 
viral units  (data not shown).  Soluble LT-ot2/I31 was much 
less active in this assay. 
The specificity of the LT-oq/132  cytotoxicity was exam- 
ined in several ways. Soluble TNF-R55  and LT-13-R im- 
munoglobulin  chimeras  (TNF-R55-Fc  and  LT-13-R-Fc) 
were tested  for their  ability to block the  various activities 
(9).  These  receptors  can bind to the  appropriate  cleft be- 
tween two subunits in the trimeric ligand structures and in- 
terfere  with  the  ability  of receptor  on  the  membrane  to 
bind  ligand.  As expected  and  shown  previously  (36,  37), 
TNF-R55-Fc  completely  blocked  TNF-induced  growth 
inhibition  by binding to TNF  and preventing its  interac- 
tion with surface receptor (Table  1).  Soluble TNF-R  had 
no  effect  on  LT-eq/132-mediated  antiproliferative  effects. 
In contrast, LT-13-1L-Fc blocked LT-~xl/132  effects, but not 
those of TNF or LT-cl. Moreover, anti-LT-ee-neutralizing 
mAbs (9) did not affect the LT-ell/13 z cytotoxicity (data not 
shown),  confirming that soluble  trace LT-et  contaminants 
were not involved in the  activity of LT-a~/13z  on HT-29 
cells.  Additionally,  a  mutated  form of LT-a  (D50N)  that 
lacks the ability to signal through the TNF-I~ was exam- 
ined  (38).  LTqxl/13  /  prepared  with  the  mutant  LT-a re- 
tained  essentially  full  activity  on  HT-29  and  WiDr  cells 
(see  below),  further  eliminating  TNF-R55  binding  as  a 
possible  mechanism for the  cytotoxic effects  of LT-oq/132 
(Ambrose,  C.,  unpublished  data).  An anti-TNF  neutraliz- 
ing  mAb  104c,  also  had  no  effect on  LT-~a~/[32  activity, 
precluding the induction of TNF synthesis as a mechanism 
for the LT-otl/132 effects. These assays indicate that LT-oq/ 
[3  z can trigger cytotoxic events via non-TNF-R-mediated 
mechanisms. 
Mechanism of Growth Inhibition.  The growth inhibition assay 
alone does not discriminate between death and stasis;  how- 
ever, direct observation of the treated HT-29 cells showed 
that  Fas  receptor  activation  led  to  rapid  cell  death,  i.e., 
within  t2-24 h, whereas TNF effects were slower and re- 
quired ~24  h.  LT-Ixl/132-treated cells underwent  a  much 
slower death,  with dead cells not being visible until  1.5-2 
d.  The morphology of the  dying cells  was identical  in all 
three  cases.  Some  cells  have  the  appearance  of apoptotic 
bodies  with  condensed nuclei,  whereas  in  others  the  nu- 
cleus appears to condense and the cytoplasm balloons out and 
becomes clear (Fig. 2).  Substantial cell lysis does not occur 
even  after  3-4  d.  The TNF-,  anti-Fas  receptor  mAb-- or 
LT-oL1/132-treated populations  had  more  cells  that  stained 
brightly with  HOECHST  dye staining  (data  not shown), 
which can be indicative of chromatin condensation accom- 
panying apoptotic events. Internucleosomal DNA fragmen- 
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Figure  1.  The cytotoxic effects of LT-eq/132 on the 
human adenocarcinoma HT-29 cells. Comparison of  the 
cytotoxic activity ofanti-Fas receptor mAb CH-11 (0), 
TNF (O), LT-cl (I-q), LT-al/132 (B), and LT-~2/I31 (0) 
in the presence and absence of  S0 U/m] IFN-  T 
869  Browning et al. Table 1.  Ability of LT-fl-R and TNF-R55 Immunoglobulin 
Fusion Proteins to Block the Inhibitory Effects of Various TNF and 
LT Ligands on HT-29 Growth 
Concentration ofcytotoxic agent 
resulting in 50% growth inhibition 
Presence of* 
Cytotoxic agent  hu-IgG control  TNF-R55-Fc  LT-[3-R-Fc 
ng lml  ng lml  ng /ml 
TNF  0.08  > 10*  0.08 
LT-oL  3.0  >1000  3.0 
LT-tx 1/132  5.0  5.0  >200.0 
Anti-Fas mAb  2.0  2.0  2.0 
*Each cytotoxic agent was premixed with the Ig fusion proteins for 10 
rain before addition to the cells. The final concentration of fusion pro- 
tein was 5 Izg/ml. 
*Higher concentrations were not tested. 
tation or laddering was not observed after LT-0tl/[~2, TNF, 
or anti-Fas treatment of HT-29 or WiDr cells,  although a 
prominent large DNA band was visible  (data  not shown) 
after all three treatments. This large fragment is reminiscent 
of the  large  50-200-kb  cleavage products  previously de- 
scribed in dying epithelial tumor cells (39,  40). Some DNA 
fragmentation was  observed using TUNEL  staining of 3' 
hydroxyl ends of DNA, which is more sensitive than DNA 
laddering (Fig. 3). Therefore, the death induced by TNF-1L, 
Fas,  or LT-[3-1L signaling may be basically apoptotic even 
though all of the classic features of apoptosis have not been 
observed in epithelial tumors (39,  41). 
Properties of Anti-LT-fl-R  mAbs.  Antibodies  to  receptors 
in the TNF family can have either antagonistic or agonistic 
effects, and as tools they have been very useful in delineat- 
ing the consequences of receptor activation. To determine 
if LT-[3-P,. cross-linking could induce  cell death,  we pre- 
pared  and  characterized  similar  LT-i3-R.-specific  mAbs. 
Mice  were immunized with  the  LT-]3-R-Fc fusion  pro- 
tein,  and a panel of mouse anti-LT-]3-P,, mAbs were iso- 
lated. These mAbs were grouped into four subsets based on 
their performance in the following assays: (a) the ability to 
cross-block each other in a mAb/antigen-binding experi- 
ment using plasmon resonance detection (i.e., a BIAcore  TM 
epitope mapping experiment); (b) the ability to block solu- 
ble LT-~-R-Fc binding to surface ligand on PMA-activated 
II-23 cells; and (c) the ability to affect LT-oq/132-induced cell 
death. The results of this analysis are summarized in Table 2. 
Epitope mapping using the BIAcore  TM  instrument defined 
four  separate  epitopes  recognized  by this  panel  of mAbs 
and  formed the  basis  of the  grouping shown  in  Table 2. 
Within  each  group,  the  mAbs  effectively blocked  each 
other.  The  group  I  mAbs  did  not  cross-block any other 
mAbs. The group II epitope partially overlapped the group 
III epitope.  We  identified  only  one  mAb,  CBE11,  with 
group IV properties, and its epitope slightly overlapped the 
BCG6 and BKA11 sites. To directly assess the ability of the 
mAbs to inhibit receptor-ligand binding, a FACS |  binding 
assay was used. Antibodies were premixed with soluble re- 
ceptor, and the ability of the receptor to bind to ligand on the 
surface of II-23 cells was quantitated. This assay has the ad- 
vantage that any agonistic activity of the antireceptor mAbs 
would  not be apparent,  mAbs from groups  I,  II, and  IV 
were effective inhibitors, suggesting that they bind close to 
the ligand binding region of the receptor (Table 2). 
In the HT-29 cytoxicity assay, all mAbs in these groups 
either  weakly  inhibited  growth  or  lacked  activity  when 
simply added to the culture in the absence of ligand (Fig.  4 
A). There was considerable variability in this assay possibly 
reflecting differing receptor densities at the start of the ex- 
periment; e.g., compare Fig. 4 A  and Table 3.  In dramatic 
contrast, when the mAbs were immobilized on the plastic, 
all mAbs were found to have potent cytotoxic activity (Fig. 
4 B), and this activity was again completely dependent on the 
presence of IFN-y. This result demonstrates that LT-]3-1< 
cross-linking is sufficient to induce  cell death.  Moreover, 
we reasoned that mAbs to two different epitopes should be 
able  to  cross-link  receptors  more  effectively, and  indeed 
Table 3 shows that certain pairs of mAbs were cytotoxic in 
solution.  In general, mAbs from two different groups had 
to be paired to get cytotoxic activity. 
In addition to the direct agonistic effects of the mAbs de- 
scribed above, we investigated the effects of the mAbs on 
ligand induced cell death. Each of the four groups of mAbs 
had  differing  effects  reinforcing  the  grouping  based  on 
BIAcore  TM  epitope  mapping.  Group  I  mAbs  primarily 
blocked  LT-txl/[32  activity with  a  small  amount  of direct 
growth inhibition occurring in the absence ofligand (Fig. 4 
C). In some experiments (data not shown), a Fab fragment 
of BDA8 was used, and the small growth inhibitory activity 
disappeared and only direct inhibition  was observed.  Such 
complex  mixed  agonist/antagonist  effects have  been  ob- 
served with anti-CD40 mAbs (42). The group II mAbs had 
complex effects that suggested mixed agonistic and antago- 
nistic  behavior (data not shown).  Group III mAbs potenti- 
ated  LT-%/[32  activity  presumably by  creating  local  re- 
gions of high  receptor density that would  enhance  ligand 
mediated  cross-linking  (Fig.  4  D),  and  there  was no  evi- 
dence of antagonistic effects.  The cytotoxic effects of TNF 
were  also  slightly  potentiated  by these  mAbs,  suggesting 
that certain signal transduction elements were facilitating or 
priming the cells  for TNF signaling.  The group IV mAb, 
CBE11,  did  not  affect ligand-mediated  cytotoxicity.  Be- 
cause the LT-[3-R.-specific mAbs can directly effect death, 
one  can  conclude  that  the  LT-[3-1L is  able  to  signal  cell 
death, and this event accounts for the cytotoxic activity of 
LT-oq/132. 
Survey of Sensitive Cell Lines.  A  series of human tumor 
lines  have  been  screened  for  sensitivity  to  cytotoxic  or 
growth-inhibitory effects of either the LT-cq/[32 ligand or 
plastic immobilized anti-LT-[3-R, mAbs in the presence of 
IFN-~/ (summarized in Table 4).  The WiDr line  (43)  was 
found to be sensitive to LT-txl/[32 in a very similar manner 
as the HT-29 line, and it is likely that this line is actually a 
870  Lymphotoxin-13  Receptor Signals Cell Death Figure 2.  Photograph  of HT-29 cells treated with IFN-~/(80 U/ml) alone or IFN-~/plus  50 ng/ml LT-ot~/[32 for 3 d ￿ 
derivative  of  HT-29  (28).  The  breast  adenocarcinoma 
MDA-MB-468  and  cervical  carcinoma  HT-3  lines  were 
growth inhibited,  and whether cell death occurred was not 
rigorously  determined.  In general,  however,  the  majority 
of tumor lines are not sensitive under these relatively fixed 
conditions.  This  survey was  complicated by the  fact that 
the sensitivity of the cells to IFN-~/varied dramatically, and 
the lines are often heterogenous, with mixtures of respon- 
sive  and  nonresponsive  cells  obfuscating  a  simple  MTT- 
based test. 
Cell surface levels of LT-[3-R. were examined to deter- 
mine whether LT-13-R presence is the determining factor 
for sensitivity to the LT ligand. Fig. 5 shows a comparison of 
LT-I3-P,. and CD40 receptor levels on four different tumor 
lines. The CD40 staining is included since its surface levels 
are very abundant on some epithehal tumor hnes, as is the 
LT-13-R. All four cell hnes are LT-~-R positive, and these 
results are typical of most nonlymphoid cells  (Mackay, F., 
and J.L. Browning,  unpublished results).  Despite the pres- 
ence of LT-[3-R on all four cell types, only HT-29 cells are 
appreciably sensitive to LT-eq/13a, indicating that sensitiv- 
ity does not correlate simply with receptor presence. In the 
TNF,  Fas,  and CD40 signahng systems, no correlation has 
ever been observed between  the  level of surface receptor 
and whether a  cell type responds biologically. Relative to 
Fas,  TNF-R55,  and TNF-R75,  LT-~-R is very abundant 
on cells.  Experiments on the HT-29 and WiDr hnes indi- 
cated that IFN-~ treatment did not upregulate the LT-~-R, 
whereas in the same experiments the Fas receptor was dra- 
matically upregulated as described previously (35). 
There was no evidence that LT-~-R signaling was cyto- 
static to normal human fibroblasts, endothelial cells,  or pri- 
mary lymphocytes, which was expected since lymphocytes 
do not express the receptor (Hochman, P., J.L. Browning, 
and C. Ware, unpublished observations). The growth of the 
human diploid fibroblastoid hne WI-38 was stimulated by 
LT-13-R signaling (data not shown).  The adenocarcinoma 
hnes SW620 and SW1417 both displayed altered morphol- 
ogy in response to LT-~-R signaling without growth arrest. 
Anti-LT-[3-R mAb Inhibits  the Gwwth of WiDr in SCID 
Mice.  We  have  explored the  ability  of an  anti-LT-~-R 
mAb, CBE11, to block the growth of the WiDr line in im- 
munodeficient  mice.  When  the  mice  were  treated  intra- 
peritoneally with the CBE11  mAb at the same time as the 
WiDr cells were inoculated subcutaneously, rumor outgrowth 
was dramatically blocked (Fig.  6 A). The antitumor action 
was enhanced by IFN-~/; however, the mAb was effective 
even without exogenous IFN-~/. In the  CBE11  +  IFN-',/ 
group, 7  of 16 animals completely lacked tumors, whereas 
the remaining animals had small nodules that had not pro- 
gressed at 2 too. The CBE11 animals treated without IFN-~/ 
were similar to the CBE11  +  IFN-',/group at 30 d; how- 
ever, these mice eventually developed slowly growing tu- 
mors. There were statistically  significant differences between 
the  control  or  IFN-~/-treated  groups  and  the  CBEll- 
treated groups, whereas no significant differences were ob- 
served  between  the  saline,  IFN-%  or  the  control  anti- 
human LFA3 mAb (1E6)  +  IFN-'y groups.  The  1E6  and 
CBEll  mAbs are both IgGls, and since the  1E6 mAb ef- 
fectively  coats  the  tumor  line  yet  did  not  block  tumor 
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Figure 3.  FACS  |  analysis  of TUNEL staining of DNA fragmentation 
occurring in response to Fas, TNF, or LT-cq/132 signaling.  HT-29 cells 
were exposed to 80 U/rrd of IFN-~/for 3 d, 50 ng/ml anti-Fas  mAb and 
IFN-'y for 2 d, 50 ng/ml LT-cq/132 and IFN-'? for 3 d, or 10 ng/ml TNF 
with IFN-~/for 2 d. All cells in the culture were stained using the Apo- 
Tag  TM  kit (Oncor, Inc.) without or with terminal deoxynucteotidyl  trans- 
ferase addition. 
Table 2.  Summary  of Mouse Anti-Human L T-~-R mAbs 
growth,  we  can exclude complement- or NK cell-medi- 
ated events as the basis for the tumor inhibition. The effi- 
cacy of CBEll  in the  absence of IFN-',/ was  unexpected 
since there was an absolute dependence on IFN-~/for any 
LT-13-K based in vitro cytotoxic effect￿9 Either there is some 
crossover of mouse IFN-~/ onto human IFN-~/ receptors, 
or  other  mechanisms are  involved in vivo.  The  mecha- 
nism(s) by which LT-13-K signaling  prevents tumor growth 
in vivo effects are being investigated. The ability of com- 
bined IFN-~//CBEll treatment to inhibit the growth of an 
established tumor was demonstrated (Fig. 6  B). Mice were 
inoculated with  106 WiDr cells, and after  15  d, treatment 
was initiated. At this point the average tumor volume was 
0.076 cc or an average diameter of 0.532 cm. Treated tu- 
mors stopped growing, and after three  injections of anti- 
body over 3 wk, growth was arrested out to 7 wk after in- 
oculation, at which point the experiment was terminated. 
Discussion 
Activation of the receptors of the TNF family can direct 
cells into a proliferative or differentiation type response, or 
it can induce cell death  sometimes even in the  same  cell 
type depending on the conditions (4, 22, 44). In this work, 
we have shown that signaling through the LT-I3-R leads to 
the death of the HT-29 and WiDr human adenocarcinoma 
cell hnes  and  is  at  least  growth  inhibitory to  two  other 
lines.  This  activity represents  the  first  observed  effect  of 
LT-13-K signaling and is important not only because of the 
current interest in cytotoxic events, but because it provides 
a biological assay for characterizing various reagents. There 
was  no evidence that LT-13-R signaling was cytostatic to 
mAb group  mAb name  Cell staining* 
HT-29 cytotoxicity 
Blocking receptor  mAb immobilized  Soluble mAb 
binding*  on Plastic~  Soluble mAb alone  with LT-0qB  1 
I  BDA8  +++  +++ 
I  AGH1  +++  +++ 
II  BCG6  + + +  + + 
II  BHA10  + + +  + + + 
Ill  BKA11  + + +  +/- 
III  CDH10  +++  +/- 
IV  CBEll  +++  +++ 
Controls 
MOPC21  -  - 
HT29/26  -  ND 
TS 2/9￿82  ND  ND 
+  +/-II  Inhibits 
+  +/-  Inhibits 
+  +/-  Mixed 
+  +/-  Mixed 
+  -  Potentiates 
+  +/-  Potentiates 
+  +/-  No effect 
No effect 
No effect 
No effect 
*FACS  |  staining of CHO cells transfected  with LT-I~-R. 
*Assay assessed whether antibody blocks binding of soluble receptor to the activated T cell hybridoma 11-23. 
~HT-29 cells were grown with IFN-~/on anti-LT-13-R.-coated  plates as described in Materials and Methods. 
IIVariable, partial inhibition in some assays, no effects in others. 
~Anti-human LFA-3, a mouse IgG1. 
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Figure  4.  Effects  ofvatious anti-LT-13-R mAbs on HT-29 growth. A 
shows the effects of soluble and-LT-tS-k mAbs alone on the growth of 
HT-29 cells; control lgG1 (Q), HT-29/26, a mAb to an irrelevant abun- 
dant surface Ag on HT-29 cells (ll  L BDA8 (O), and CDH10 ([]). B il- 
lustrates the direct cytotoxic effects of these two anti-LT-13-R, mAbs on 
HT-29 cells when immobilized on the plastic surface. Plates were coated 
with IgG1 (O), HT-29/26 (11), BDA8 (O), and CDH10  (l-q). C shows 
the LT-eq/~2 antiproliferative effects on HT-29 cells in the presence of 2 
wg/ml control IgGl (11) or anti-LT-13-R,  rnAb BDA8 (~). BDA8 exhib- 
its some agonist activity even at low concentrations. D shows the effects 
of CDH10 as an example of a group 11I anti-LT-13-R mAb that potenti- 
ates the effects  ofLT-txx/~3  z. LT-eq/~2 effects were measured in the pres- 
ence of no mAb (O), 0.5 ~g/ml control lgG1 (I), 0.05 ~g/ml CDH10 
((3), and 0.5 Ixg/ml (fq) CDHI0. 
nontransformed  cells,  and  signaling  could  actually  drive 
growth in some situations. This pattern of cell sensitivity to 
LT-oq/[32 basically resembles the effects of TNF. The data 
we have obtained suggest that the cytotoxicity mediated by 
the LT-~-R  will be limited to transformed cells, tEecenfly, 
signaling through TNF-R75  has been reported to mediate 
an unusually slow death of nontransformed activated lym- 
phocytes (23, 24), indicating that TNF-induced death may 
not be limited to transformed cells. In contrast,  nontrans- 
formed lymphocytes can be induced to undergo rapid apop- 
tosis after Fas signaling, and this event is most likely to be 
involved in the deletion of certain lymphocyte populations 
in the periphery (22, 45). Whether the slow events involv- 
ing LT-J3-R or TNF-R75 are physiologically  important will 
require further investigation. Surface LT is abundant on lym- 
phokine  activated T  cells,  i.e.,  LAK cells  (12,  46).  Cur- 
rendy, cell mediated cytotoxicity is thought to be mediated 
through  the  perforin  and/or  Fas pathways  (47).  A  classic 
LT-~-R-positive NK/LAK target, K562, was found to be 
completely resistant to the action of soluble LT-txl/~2, sug- 
gesting that neither surface LT is not involved in NK-like 
cytotoxicity.  Genetic  disruption  of  LT--a  and  the  two 
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Table  3.  Effect  of Pairs of  Anti-LT-O-R mAbs on HT-29/WiDr 
Growth 
mAb  Concentration  mAb  Concentration  Cell growth 
(ng/ml)  (nglml)  (OD 550 rim) 
IgG1  200  0.77 (HT-29) 
BDA8  100  --  --  0.33" 
--  --  BCG6  100  0.50 
BDA8  100  BCG6  100  0.05 
IGG1  50  --  --  0.85 (HT-29) 
CDH10  33  --  --  0.525 
--  --  AGH1  50  0.49 
CDH10  33  AGH1  50  0.23 
IgG1  100  --  --  0.80 (HT29) 
CDH10  10  --  --  0.86 
IgG1  50  CDH10  10  0.81 
--  --  CBE11  50  0.58 
CDH10  10  CBE11  50  0.21 
BHA10  10  --  --  0.85 
BHA10  10  CBE11  50  0.09 
IgG1  50  --  --  0.62 (WiDr) 
CDH10  33  --  --  0.36 
--  --  AGHI  50  0.36 
CDH10  33  AGH1  50  0.16 
Dotted lines indicate separate experiments. 
*Typically, further increases in the mAb concentration did not increase 
the amount of growth inhibition. 
TNF-R  does not impair CTL-mediated cell death support- 
ing the hypothesis that TNF/LT  signaling is not involved in 
cell-cell killing (13). Further experimental work will be re- 
quired to determine whether LT signaling via direct cell- 
cell contact supports these conclusions. 
The LT system with its heterotrimeric ligand is unusual. 
The  cytotoxic activity resides primarily in  the  LT-~1/132 
form, with the LT-cx2/131  complex being much less active. 
The  crystal structure  of LT-ot complexed with  the TNF- 
P,.55 revealed that the receptor lies in the groove between 
two adjacent subunits (48). The higher potency of the LT- 
~x1/132 form suggests that the [3/[3  cleft, which is unique in 
the LT-oq/f3 z heterotrimer, must interact with the LT-13-R. 
Biochemical  analyses  of this  interaction  have  confirmed 
that there is a high affinity interaction of LT-I3-R with LT- 
cxl/132  and  a  lower  affinity  interaction  with  LT-a2/BI 
(Browning, J.L.,  M.  Zafari,  C.  Benjamin,  W.  Meier,  D. 
Griffiths, and K. Miatkowski, unpublished observations). The 
exact nature of the signaling complex is currently unclear. 
Antibodies to the TNF-K55  (49,  50),  Fas receptor (21, 
35,  51),  CD27  (52),  and  CD40  (53)  have been  shown  to 
have receptor-activating properties. Presumably antibodies Table  4.  Summary of the Effects of TNF, Anti-Fas, L T-oel  /A82, and Anti-L T-~8-R on the Growth of Various Cells in the Presence of lFN-y 
Growth inhibition by 
Name  Type  TNF  Anti-Fas  LT-oq/[32  Anti-LT-[3-1K 
Brain 
Ul18 
SW1783 
SW1088 
Skin 
A375 
SK-MEL-1 
Colorectal 
HT29 
WiDr 
SK-Co-1 
SW 403 
SW 480 
SW 620 
SW 837 
SW  1116 
SW  1417 
Colo 320DM 
LoVo 
DLD-1 
LS  174T 
LS  123 
T84 
HCT  116 
NCI  H508 
CACO-2 
Breast 
BT-20 
SK-BR.-3 
MCF-7 
MDA-MB-468 
Cervix 
ME180 
HT-3 
MS751 
Ovary 
SK-OV-3 
Pancreas 
PANC-1 
Capan-1 
Capan-2 
Lung 
A549 
Lymphoid 
U937 
K562 
Glioblastoma  +/-  +/- 
Astrocytoma  -  +  + 
Astrocytoma  +  +/-- 
Melanoma 
Melanoma 
Adenocarcinoma 
Adenocarcinoma 
Adenocarcinoma 
Adenocarcinoma 
Adenocarcmoma 
Adenocarclnoma 
Adenocarcmoma 
Adenocarcmoma 
Adenocarclnoma 
Adenocarcinorna 
Adenocarcinoma 
Adenocarcmoma 
Adenocarcmoma 
Adenocarcinoma 
Carcinoma 
Carcinoma 
Adenocarcinoma 
Adenocarcinoma 
m  m 
h 
ND 
++  ++  ++  ++ 
++  ++  ++  ++ 
++  ++  --  _ 
--  ++  --  _ 
+  +  --  _ 
+/--  +/--  --  _ 
-  +  -  ND 
-  -  *  ND 
-  ND  -  ND 
+  +/-  -  _ 
+  +  -  +/- 
++  +/-  -  _ 
+  -  -  ND 
+  ++  -  _ 
+/-  -  -  ND 
+  +  +  -  ND 
Carcinoma  +  +  -  -  ND 
Carcinoma  +/-  -  +/-*$11  - 
Adenocarcinoma  +  +  +  +/-*11  ND 
Adenocarcinoma  +  +  ND  +/-  ~  + 
Carcinoma 
Carcinoma 
Carcinoma 
Adenocarcinoma 
+  + 
++ 
+a  +/_ 
Epitheloid carcinoma  +  + 
Adenocarcinoma  -  +  + 
Adenocarcinoma  -  +  + 
+/-  ND 
+/-II 
++* 
+/-If 
Carcinoma 
Histiocytic  +  +  +/- 
Promyelocytic  -  - 
+ 
+/- 
ND 
ND 
ND 
* Some growth stimulation. 
*Altered morphology. 
~Heterogenous cell population, responders and nonresponders present. 
IIUnconfirmed ifLT-ot component. LT-~ Receptor 
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Figure  5.  FACS  |  analysis comparing CD40  and LT-~-R levels on 
three  colorectal carcinoma lines, HT-29,  SW620, HCT  116, and the 
pancreatic carcinoma CAPAN-2.  Untreated cells were stained with anti- 
CD40  (BB20), anti-LT43-R (BDA8), or a control mAb (MOPC  21). 
Control  antibody staining is the curve with the lowest staining in each 
panel. 
capable of cross-linking the receptors in the right orienta- 
tion  will  generate  receptor  aggregates  that  can  signal. 
Dimerization of the TNF-R55  may be suflficient to trigger 
TNF  signaling;  however,  in  the  Fas receptor  case,  larger 
aggregates need to be formed (54). When immobilized on 
a  plastic surface,  all the  anti-LT-J3-R mAbs were  able to 
induce death, including those that blocked ligand binding. 
Similar patterns  were  shown  for  anti-Fas  receptor  mAbs 
(51). In contrast, the anti-LT-[3-R mAbs were not very ef- 
fective in  solution  unless  mAbs  to  two  different epitopes 
were mixed together. In this case, it can be envisioned that 
aggregates larger than dimers could form, resulting in more 
productive signaling. When combined with the LT-oq/~2 
ligand, some antibodies blocked activity, presumably by di- 
rectly blocking the binding site, e.g., BDA8 and AGH1, al- 
though  there was  some  evidence for mixed agonistic/an- 
tagonistic effects even in this case. At the other end of the 
spectrum, some mAbs, e.g., CDH10  and BKA11, potenti- 
ated the killing induced by ligand. Again, cross-linking of 
the receptor into small aggregates presumably facilitates the 
ability ofligand to productively cross-link and signal. Inter- 
estingly,  the  synergistic effect  of the  anti-LT-13-R  mAbs 
with the LT-al/J32 ligand also occurred between anti-LT- 
13-R mAbs and TNF.  We do not have  any evidence that 
the TNF  receptors are involved in LT-I3-R signaling, and 
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Figure  6.  Growth  of the  human  adenocarcinoma WiDr  tumor  in 
SCID mice. A shows the size of  tumors 30 d after inoculation. Mice were 
treated on days 0 and 1 with saline, IFN-~/alone, an anti-LT-~3-R mAb 
CBE11 with and without IFN-7, and a control anti-human  LFA3 mAb 
IE6 with IFN-  7. Animals treated with CBE11 or 1E6, represented by cir- 
cles with dots, received 10 I~g/mouse per injection of antibody instead of 
50 I,  Lg for the open-circle animals. The mean of each group is indicated 
by a crossbar.  Means, standard deviations, and (number  of  animals) for the 
five groups (left  to right) were 0.88 -+ 0.59 (14), 1.21 + 0.7 (21), 0.041 -+ 
0.052 (16), 0.11 + 0.1 (12) and 0.98 -+ 1.16 (12). B shows the growth of 
WiDr tumors as per A, however, the tumors were grown to an average 
diameter of 0.53 cm (0.076 cc) without any treatment, then intraperito- 
neal injections were started on day 15 and continued as indicated by the 
arrows. Animals were treated with IFN-"/ alone (106 U/injection)  ([2]), 
IFN-  7 with 50 ~g 1E6 anti-LFA-3 (O), or IFN-  7 with 50 I~g CBEll 
anti-LT-J3-R (A). Means and standard deviations are indicated for groups 
of 12 animals. 
therefore we interpret the effects on TNF  signaling as re- 
suiting from more complex priming-like events at the in- 
tracellular level.  Anti-LT-J3-R  mAbs  can  trigger NF-KB 
activation without inducing cell death (MacKay, F., manu- 
script  submitted  for  publication),  thus  it  is  possible  that 
both the LT-J~-R and TNF-R  intracellular signal transduc- 
tion pathways utilize some common  elements resulting in 
synergistic cross  talk.  Along with  the  soluble hgands  and 
LT-I3-R-Fc forms, the anti-LT-13-R mAbs are good tools 
for  either  activating  or  inhibiting  the  LT-J3-R  signaling 
pathway. 
TNF  can  induce  necrosis,  apoptosis,  or  mixed mecha- 
nisms,  depending  on  the  cell line  (55,  56),  whereas  Fas- 
triggered death is generally described as occurring by apop- 
tosis.  TNF  can  have  either  fast  or  slow  effects  on  cells, 
probably reflecting multiple mechanisms  (57).  The experi- 
ments described here showed a lack of classical DNA  lad- 
dering,  although  some DNA  cleavage was  detected using 
TUNEL  techniques.  The  nuclei  appear to  condense,  yet 
the cytoplasm balloons out in a manner characteristic of ne- 
crosis. It is possible that the ballooning occurs long after the 
death event and is observed in these assays, which are rela- 
tively long term compared with conventionally studied ap- 
optotic events. Morphologically, the death induced by TNF, 
anti-Fas receptor, and LT-%/J32 are similar, differing only 
kinetically. The  signaling pathways  initiated in  each  case 
may be different, as shown previously for Fas and TNF re- 
ceptors (58, 59). The action of TNF is often accelerated by 
875  Browning eta]. the addition ofcycloheximide to the culture, and the HT-29 
cells are no exception. In contrast, LT-~I/~2 lacked activ- 
ity in the standard short term cycloheximide-containing as- 
say. Either the LT-~I/I32 action required protein synthesis, 
or  the  cytotoxic  events  are  simply  too  slow  to  manifest 
themselves in the short-term assay format. In the TNF case, 
the signaling pathways leading to death are likely to be dif- 
ferent  depending  on  whether  or  not  cycloheximide  is 
present  (60).  The  effects of cycloheximide  and  the  slow 
pace of LT-IB-1L-induced death  relative  to  TNF  and  Fas 
suggest that LT-I3-R acts via a different pathway. This con- 
cept is intriguing since the LT-13-R lacks a canonical death 
domain.  Either  receptor cytoplasmic domains lacking the 
death domain can signal death,  or the LT-I3-1K undergoes 
complex  ill-defined  interactions  with  other  receptors.  In 
light of the recent observations on the slow death mediated 
by TNF-R75  (23,  24), which also lacks a canonical death 
domain,  it is possible that there are other death pathways 
used by some TNF family members distinct from that typi- 
fied by the well-studied Fas system. 
The ability to induce  death selectively in tumor cells  is 
an attractive goal. The signaling mediated by the TNF fam- 
ily of receptors is intriguing since this is one of relatively 
few cases in which a normal physiological signal can induce 
cell death as opposed to the loss of a signal, e.g., IL-2 or IL-3 
removal. The use of TNF to treat cancers was predicated 
on this concept even before the emergence of programmed 
cell death as an important physiological process. Activation 
of the LT-I3-1K with the CBE11  mAb in vivo blocked the 
growth  of WiDr  cells inoculated  into  SCID  mice.  Since 
the anti-human LT-I3-1K mAb cannot bind to mouse cells, 
the growth inhibition mechanism must directly target the 
tumor cell. Likewise, the exogenously added IFN-~ can act 
only on the tumor cells since mouse IFN-~/does not bind 
to  human  IFN-~/ receptors  (61)  and  human  IFN-~/ does 
not bind to mouse IFN-~/receptors. Therefore, because of 
the lack of an absolute requirement for IFN-% it remains 
unclear whether the in vivo effect reflects direct cytotoxic- 
ity as observed in vitro or whether other mechanisms are 
contributing.  If other  mechanisms  are  involved,  a  wider 
range  of tumors  may be  affected in  vivo  than  would  be 
forecast by the in vitro analyses.  Generally, more primary 
tumors were found to be affected by TNF in in vivo mod- 
els  than  would  be surmised from the  analysis  of in  vitro 
cultured tumor lines (62). 
An LT-IB-1K--based antitumor strategy may be important 
when considered in the context of recent advances. TNF, 
Fas,  and  LT-eq/f32  are  clearly  cytotoxic  to  tumor  types 
with mutant p53 such as HT-29 (63),  and, moreover, the 
TNF signaling pathway in cells offibroblastoid or epithelial 
origin is not sensitive to the protective effects ofbcl-2 (64). 
Therefore, the induction of a death sequence might occur 
via a route that circumvents the wild-type p53 dependency 
of some chemotherapeutic  approaches (65).  A  proper un- 
derstanding of these signaling processes may lead to alterna- 
tive  strategies  for  controlling  cancer.  Clinically,  isolated 
limb  perfusion  with  TNF  dramatically  demonstrated  the 
soundness of the approach (66),  but unfortunately the sys- 
temic application of TNF was frustrated by dose-limiting 
toxicity resulting from activation of inflammatory cascades. 
Likewise, the Fas receptor is widely distributed, and anti-Fas 
mAbs can be very potent inducers  of apoptosis; however, 
receptor activation also  leads  to  rapid  necrosis  of normal 
liver cells and death in mice. This activity would certainly 
complicate its therapeutic application (67).  The LT-IB-1K is 
present  on most transformed cell types,  and its activation 
also presents a potential anticancer therapy. Moreover, it is 
likely that sufficient IFN-~/exists in the tumor environment 
to  synergize with LT-oq/f32  without  exogenous  adminis- 
tration  (68).  Our preliminary data indicate that LT-oq/132 
does  not  effectively activate  primary  human  endothelial 
cells  to  express the VCAM  or E-setectin  adhesion mole- 
cules,  and  hamster  anti-m-LT-lB-R  mAbs  do  not  cause 
death  (Hochman,  P.,  G.  Majean,  F.  Mackay,  and  S. 
Browning,  manuscript  submitted  for publication);  there- 
fore, LT-IB-R signaling should lack TNF-type toxicity.  If 
the physiological activity of LT-Ixl/~2 is limited  to more 
subtle regulatory effects on lymph node function, it is con- 
ceivable that an LT-r  therapy may provide an alterna- 
tive therapy for some adenocarcinomas. 
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